Literature DB >> 19818293

Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients.

Peteris Tretjakovs1, Antra Jurka, Inga Bormane, Vitolds Mackevics, Indra Mikelsone, Liga Balode, Dace Reihmane, Inga Stukena, Guntis Bahs, Juris Imants Aivars, Valdis Pirags.   

Abstract

BACKGROUND: Although many studies have shown that the metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) both are associated with chronic inflammatory state and are risk factors for coronary artery disease (CAD), it is still unclear which condition is a more important contributor to the increased production of inflammatory chemokines. The purpose of this study was to assess monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels and their association with insulin resistance and adiponectin concentrations in CAD patients, who were categorized as having T2DM, MS, or neither.
METHODS: CAD male patients were categorized into three groups: 24 non-obese patients with T2DM (D), 24 obese patients with MS (M) and 24 patients without T2DM or MS (W). 20 healthy subjects were selected as controls (C). Insulin resistance was assessed by the HOMA-IR method, but serum MCP-1, IL-8, and adiponectin levels were measured by xMAP technology.
RESULTS: Serum levels of MCP-1 and IL-8 in D and M groups were increased in comparison with W and C groups (p<0.001, p<0.01), but the increase in the M group was significantly higher than that in the D group (p<0.05, p<0,001), besides MCP-1 and IL-8 concentrations were correlated with HOMA-IR indexes (r=0.52; r=0.49, p<0.0001) and adiponectin levels (r=-0.59, p<0.0001). The M group demonstrated a diminution in the adiponectin level (p<0.01) and pronounced increase of HOMA-IR in comparison with the other three groups (p<0.01).
CONCLUSION: Obese CAD patients with MS have a more pronounced increase of MCP-1, IL-8 and HOMA-IR and more decreased adiponectin levels than non-obese CAD patients without MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818293     DOI: 10.1016/j.ejim.2009.08.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  12 in total

1.  Cardiovascular risk in obese diabetic patients is significantly reduced one year after gastric bypass compared to one year of diabetes support and education.

Authors:  Alessandro Mor; Philip Omotosho; Alfonso Torquati
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

Review 2.  Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure?

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2018-06

3.  Contribution of transcription factor EB to adipoRon-induced inhibition of arterial smooth muscle cell proliferation and migration.

Authors:  Yun-Ting Wang; Jiajie Chen; Xiang Li; Michihisa Umetani; Yang Chen; Pin-Lan Li; Yang Zhang
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-04       Impact factor: 4.249

4.  Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients.

Authors:  Stacy A Brethauer; Helen M Heneghan; Shai Eldar; Patrick Gatmaitan; Hazel Huang; Sangeeta Kashyap; Heather L Gornik; John P Kirwan; Philip R Schauer
Journal:  Surg Endosc       Date:  2011-03-17       Impact factor: 4.584

5.  Should we target obesity in advanced heart failure?

Authors:  Amanda R Vest; James B Young
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

Review 6.  Nonalcoholic fatty liver disease and the coronary artery disease.

Authors:  Sombat Treeprasertsuk; Francisco Lopez-Jimenez; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 7.  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Authors:  Jun Panee
Journal:  Cytokine       Date:  2012-07-04       Impact factor: 3.861

8.  Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients.

Authors:  Hazel Huang; Takhar Kasumov; Patrick Gatmaitan; Helen M Heneghan; Sangeeta R Kashyap; Philip R Schauer; Stacy A Brethauer; John P Kirwan
Journal:  Obesity (Silver Spring)       Date:  2011-05-05       Impact factor: 5.002

9.  Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.

Authors:  Robert Klempfner; Jonathan Leor; Alexander Tenenbaum; Enrique Z Fisman; Ilan Goldenberg
Journal:  Cardiovasc Diabetol       Date:  2012-06-06       Impact factor: 9.951

10.  Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis.

Authors:  Xiongfeng Pan; Atipatsa C Kaminga; Shi Wu Wen; Aizhong Liu
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.